Eplerenone: A selective aldosterone receptor antagonist for patients with heart failure

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 68-76

  Barnes, Brian J ^a,b   Howard, Patricia A ^b  

^a Department of Pharmacy Practice ^*  (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Aldosterone receptor antagonist; Eplerenone; Heart failure; Left ventricular dysfunction

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; ANDROGEN RECEPTOR; CYTOCHROME P450; EPLERENONE; POTASSIUM; PROGESTERONE RECEPTOR; SPIRONOLACTONE;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOTENSION; IMPOTENCE; KIDNEY FUNCTION; MASTALGIA; MEDLINE; NONHUMAN; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SIDE EFFECT; SURVIVAL; TABLET; TOXICOLOGY; TREATMENT CONTRAINDICATION;

ALDOSTERONE ANTAGONISTS; ANIMALS; CARDIOVASCULAR AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS; SPIRONOLACTONE;

EID: 11144226484     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E306     Document Type: Review

References (41)

1. Heart disease and stroke statistics - 2004 update. Dallas: American Heart Association, 2003.
2. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
3. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail 1999;5:357-82. Erratum 2000;6:74.
4. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101-13.
5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
6. Zillich AJ, Carter BL. Eplerenone - a novel selective aldosterone blocker. Ann Pharmacother 2002;36:1567-76. DOI 10.1345/aph.1C027
7. Package insert. Inspra (eplerenone). New York: Pfizer, October, 2003.
8. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345:1689-97.
9. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.
10. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, et al. Production of aldosterone in isolated rat blood vessels. Hypertension 1995;25:170-3.
11. Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-800.
12. Ullian ME, Islam MM, Robinson CJ, Fitzgibbon WR, Tobin ET, Paul RV. Resistance to mineralocorticoids in Wistar-Furth rats. Am J Physiol 1997;272(3 pt 2):H1454-61.
13. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999;33:232-7.
14. Horiuchi M, Nishiyama H, Hama J, Takenaka T, Kondo H, Kino H, et al. Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol 1993;264(2 pt 2):F286-91.
15. Staessen J, Lijnen P, Fagard R, Verschueren IJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65.
16. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.
17. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;12:308-14.
18. Rajagopalan S, Pitt B. Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep 2001;3:240-8.
19. Funder JW. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J 2002;144(5 suppl):S8-11.
20. Liew D, Krum H. The role of aldosterone receptor blockade in the management of cardiovascular disease. Curr Opin Investig Drugs 2002;3: 1468-73.
21. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85:336-44.
22. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408-11.
23. Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002;62:723-31.
24. Rajagopalan S, Pitt B. Aldosterone as a target in congestive heart failure. Med Clin North Am 2003;87:441-57.
25. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.
26. Zhang ZH, Francis J, Weiss RM, Felder RB. The renin-angiotensin- aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 2002;283:H423-33.
27. Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 2003;108:1790-4.
28. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-6.
29. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-72.
30. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002;40:304-10.
31. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, et al. Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6.
32. Abshagen U, Rennekamp H, Luszpinski G. Pharmacokinetics of spironolactone in man. Naunyn Schmiedebergs Arch Pharmacol 1976; 296:37-45.
33. Overdiek HW, Merkus FW. Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 1986;40:531-6.
34. Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 1989;29:342-7.
35. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-21.
36. Dormarunno K. Eplerenone Post-acute myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS). Data on file, Pfizer, 2004.
37. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.
38. Cohen HE. Drug topics red book. 2004 ed. Oradell, NJ: Thomson Healthcare, 2004.
39. Click HA, Orzol SM, Tooley JF, Remme WJ, Sasayama S, Pitt B. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Ther 2002;16:53-9.
40. Spertus JA, Tooley J, Jones P, Poston C, Mahoney E, Deedwania P, et al. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am Heart J 2002;143:636-42.
41. Davis B (primary investigator). HARP trial information. www.sph. uth.tmc.edu/harp/ and http://apps.nhlbi.nih.gov/popstudies/contacts.asp? trialnumber=160 (accessed 2004 Jun 16).